| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/25/2005 | US6846805 Oligopeptides or polypeptides used to inhibit transmembrane proteases such as aspartyl secretases, administered for prophylaxis of neurodegenerative diseases; Alzheimer's disease |
| 01/25/2005 | US6846802 Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties |
| 01/25/2005 | US6846799 Administering epidermal growth factor antagonist; blocking with antibody; chronic obstructive pulmonary disease |
| 01/25/2005 | US6846676 In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy |
| 01/25/2005 | US6846674 Gene, encoding a subunit of the transcription factor AP-1, of its genome is inactivated and/or a component, acting on the AP-1 transcription factor, of the signal transduction pathway is modified resulting in a modified AP-1 activity and |
| 01/25/2005 | US6846672 Mitogenic oxygenase regulators |
| 01/25/2005 | US6846670 Expressing heterologous nucleotide sequences in cells; obtain vascular cells, incubate with herpes virus, monitor propagation of virus in central nervous system |
| 01/25/2005 | US6846650 Nucleotide sequences coding polypeptide for use in the imaging, diagnosis, treatment classification and prevention of lung cancer |
| 01/25/2005 | US6846640 Identifying modulators of polypeptide aggregation; for treating alzheimer's, down's syndrome, huntington's, parkinson's, prion, amyotrophic lateral sclerosis, lewy bodies and/or diabetic diseases |
| 01/25/2005 | US6846623 LGMD gene coding for a calcium dependent protease |
| 01/25/2005 | US6846477 One dose vaccination with Mycoplasma hyopneumoniae |
| 01/25/2005 | US6846476 Treatment of B-cell associated diseases |
| 01/25/2005 | CA2309352C Heterocyclic-substituted tricyclics as thrombin receptor antagonists |
| 01/25/2005 | CA2179377C Method of treatment of hormone-unresponsive metastatic prostate cancer |
| 01/25/2005 | CA2123224C Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of t-lymphocytes |
| 01/25/2005 | CA2103383C Quinazoline derivatives |
| 01/20/2005 | WO2005006807A1 Transmitter of wireless microphone, receiver for wireless microphone, mobile information communication apparatus, and communication system for wireless microphone |
| 01/20/2005 | WO2005006806A1 Wireless microphone communication system |
| 01/20/2005 | WO2005004926A1 Dendritic cell infiltrativity activating composition and immune activator |
| 01/20/2005 | WO2005004898A1 Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer |
| 01/20/2005 | WO2005004892A1 Plant worms mycelium extracat fraction and composition for oral intake |
| 01/20/2005 | WO2005004856A1 Antifungal composition |
| 01/20/2005 | WO2005004838A1 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 01/20/2005 | WO2004069142A3 Anti-candida agents for the treatment of prion diseases |
| 01/20/2005 | WO2003076443A9 Spiro compounds with npy antagonistic activity |
| 01/20/2005 | WO2003072114A8 Vascular therapeutics |
| 01/20/2005 | WO2002050289A8 Methods for the production of multimeric proteins, and related compositions |
| 01/20/2005 | US20050015820 Using transgenic mouse tissue as model for monitoring agents that affect appetite, energy expenditure and caloric and food intake; dietetics and weight gain |
| 01/20/2005 | US20050014941 Cyanoalkylamino derivatives as protease inhibitors |
| 01/20/2005 | US20050014938 Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase |
| 01/20/2005 | US20050014843 Utilizing tomoxetine compound or such as n-ethyl-3-phenyl-3-(2-butylthiophenoxy)propyl-amine; attention deficit, hyperactivity, involuntary repetitive movement or sound disorders, tourette's syndrome |
| 01/20/2005 | US20050014841 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 01/20/2005 | US20050014835 Agents for Treating Diseases Caused by Nonsense Mutations |
| 01/20/2005 | US20050014831 Cancer, hypertension, obesity; diseases mediated by alteration of membrane structure and regulation of G-proteins or receptors |
| 01/20/2005 | US20050014827 Formulations containing polyphenol derivatives; food and feed supplements; bactericidal, fungicidal and virucidal effects |
| 01/20/2005 | US20050014819 Prenylflavonoids, chalcone derivatives, flavonols and/or glycosides; plant extracts; foods, beverages; insulin resistance |
| 01/20/2005 | US20050014815 Substituted 2-pyrrolidine-2-yl-1H-indole compounds |
| 01/20/2005 | US20050014811 Such as 4-cyclopentylamino-benzenesulfonic acid 2-(3,4-dimethoxy-phenylamino)-1H-benzoimidazol-5-yl ester; cyclin-dependent kinase inhibitors that are aimed to be more active than flavopiridol |
| 01/20/2005 | US20050014808 Combined agents for treatment of glaucoma |
| 01/20/2005 | US20050014803 Enzyme inhibitors |
| 01/20/2005 | US20050014800 Vision defects; anticancer agents; antitumor agents |
| 01/20/2005 | US20050014798 Blending mixture of rosiglitazone and maleic acid; salt formation; crystal structure; antidiabetic agents |
| 01/20/2005 | US20050014788 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 01/20/2005 | US20050014781 Ring fused pyrazole derivatives as CRF antagonists |
| 01/20/2005 | US20050014776 Steroidal compounds for inhibiting steroid sulphatase |
| 01/20/2005 | US20050014775 Anticancer agents |
| 01/20/2005 | US20050014769 Anticancer agents; controlling apoptosis |
| 01/20/2005 | US20050014768 Antiinflammatory agents; analgesics |
| 01/20/2005 | US20050014757 Serotonin receptor antagonist; psychological disorders; side effect reduction |
| 01/20/2005 | US20050014746 compounds which bind to the interaction-domain (I-domain) of LFA-1, thus interrupting endothelial cell-leukocyte adhesion by blocking the interaction of LFA-1 with ICAM-1, ICAM-3, and other adhesion molecules |
| 01/20/2005 | US20050014744 Benzothiazine and benzothiadiazine compounds |
| 01/20/2005 | US20050014741 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/20/2005 | US20050014740 E.g. 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or piperazine or hydrochloride or oxalate; treating depression, anxiety, and obsessive compulsive disorders |
| 01/20/2005 | US20050014726 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
| 01/20/2005 | US20050014721 reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids |
| 01/20/2005 | US20050014705 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/20/2005 | US20050014703 Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator |
| 01/20/2005 | US20050014701 Synergistic mixture; anticoagulants |
| 01/20/2005 | US20050014699 Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 01/20/2005 | US20050014696 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 01/20/2005 | US20050014695 Uses of a chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes |
| 01/20/2005 | US20050014675 Therapy for vascular system disease; using growth hormonr secretion promoter compound ; artheriosclerosis; cardiovascular disorders; anticholesterol agents |
| 01/20/2005 | US20050014258 Methods for altering cell fate |
| 01/20/2005 | US20050014242 Expression vector comprising nuclelotide sequences coding seriene protease for use as therapeutic protein in treatment of inflammatory, reproductive, epidermal and neurological tissue disorders |
| 01/20/2005 | US20050014232 Novel tetronic acid derivative |
| 01/20/2005 | US20050014188 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 01/20/2005 | US20050014149 Assay for inhibitors of translocases |
| 01/20/2005 | US20050013879 Method for extracting antineoplastic components from Bupleurum scorzonerifolium |
| 01/20/2005 | US20050013864 In situ administering; mixture of bone morphogenic protein and ethylene oxide-propylene oxide copolymer |
| 01/20/2005 | US20050013862 Functional powders for oral delivery |
| 01/20/2005 | US20050013830 Containing cordyceps sinensis or extract; suppressing decrease of spongy bone density |
| 01/20/2005 | US20050013823 Administering to animal at 3 to 10 days of age; swine |
| 01/20/2005 | US20050013808 Nitroreductase enzymes |
| 01/20/2005 | US20050013791 Cytokine-inducing material and cytokine-inducing instrument |
| 01/20/2005 | DE10329716A1 Verbesserung der Schlupffähigkeit bei eierlegenden Tieren Improving hatchability in oviparous animals |
| 01/20/2005 | CA2531636A1 Compositions for activating the infiltration activity of dendritic cells and immunopotentiating agents |
| 01/19/2005 | EP1498491A1 METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa |
| 01/19/2005 | EP1498490A1 Process for producing antibody composition |
| 01/19/2005 | EP1498427A1 Immunoglobulins devoid of light chains |
| 01/19/2005 | EP1498406A1 Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand |
| 01/19/2005 | EP1498145A1 DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME |
| 01/19/2005 | EP1498139A1 Novel thrombomodulin expression promoters |
| 01/19/2005 | EP1498127A1 Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 01/19/2005 | EP1498126A1 Neurotrophic factor production accelerator |
| 01/19/2005 | EP1498125A1 Use of compounds having ccr antagonism |
| 01/19/2005 | EP1498124A2 The use of inhibitors of the renin-angiotensin system |
| 01/19/2005 | EP1498121A1 Use of specific cyclolignans |
| 01/19/2005 | EP1498101A1 Composition for cell proliferation |
| 01/19/2005 | EP1497662A1 Uses of the carbamoyl phosphate synthesis 1 (cps 1) and the fragments thereof for the diagnosis of inflammatory diseases and sepsis |
| 01/19/2005 | EP1497659A2 An ephrin-b receptor protein involved in carcinoma |
| 01/19/2005 | EP1497466A2 Binary or polynary targeting and uses thereof |
| 01/19/2005 | EP1497438A1 Means and methods for the production of adenovirus vectors |
| 01/19/2005 | EP1497436A1 Compositions for delivering enzymes involved in amino acid metabolism using recombinant adeno-associated virus virons (raav virons), and method and use for treating amino acid metabolic disorders using such raav virons |
| 01/19/2005 | EP1497425A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| 01/19/2005 | EP1497419A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof |
| 01/19/2005 | EP1497334A2 Protein stabilisation using chaperone proteins |
| 01/19/2005 | EP1497330A2 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| 01/19/2005 | EP1497319A2 Cell adhesion and extracellular matrix proteins |
| 01/19/2005 | EP1497308A1 Method for producing steroid crystals, crystals obtained by said method and their use in pharmaceutical formulations |
| 01/19/2005 | EP1497306A1 Alternatively spliced nucleic acid molecules |